title: Novel PET probes specific for deoxycytidine kinase.
abstract: Deoxycytidine kinase (dCK) is a rate-limiting enzyme in the deoxyribonucleoside salvage pathway and a critical determinant of therapeutic activity for several nucleoside analog prodrugs. We have previously reported the development of 1-(2'-deoxy-2'-(18)F-fluoro-beta-D-arabinofuranosyl)cytosine ((18)F-FAC), a new probe for PET of dCK activity in immune disorders and certain cancers. The objective of the current study was to develop PET probes with improved metabolic stability and specificity for dCK. Toward this goal, several candidate PET probes were synthesized and evaluated in vitro and in vivo.
  
  
  METHODS
  High-pressure liquid chromatography was used to analyze the metabolic stability of (18)F-FAC and several newly synthesized analogs with the natural D-enantiomeric sugar configuration or the corresponding unnatural L-configuration. In vitro kinase and uptake assays were used to determine the affinity of the (18)F-FAC L-nucleoside analogs for dCK. The biodistribution of selected L-analogs in mice was determined by small-animal PET/CT.
  
  
  RESULTS
  Candidate PET probes were selected using the following criteria: low susceptibility to deamination, high affinity for purified recombinant dCK, high uptake in dCK-expressing cell lines, and biodistribution in mice reflective of the tissue-expression pattern of dCK. Among the 10 newly developed candidate probes, 1-(2'-deoxy-2'-(18)F-fluoro-beta-L-arabinofuranosyl)cytosine (L-(18)F-FAC) and 1-(2'-deoxy-2'-(18)F-fluoro-beta-L-arabinofuranosyl)-5-methylcytosine (L-(18)F-FMAC) most closely matched the selection criteria. The selection of L-(18)F-FAC and L-(18)F-FMAC was validated by showing that these two PET probes could be used to image animal models of leukemia and autoimmunity.
  
  
  CONCLUSIONS
  Promising in vitro and in vivo data warrant biodistribution and dosimetry studies of L-(18)F-FAC and L-(18)F-FMAC in humans.
authors.affiliation: Division of Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
authors.forename: Chengyi J
authors.initials: CJ
authors.lastname: Shu
authors.forename: Dean O
authors.initials: DO
authors.lastname: Campbell
authors.forename: Jason T
authors.initials: JT
authors.lastname: Lee
authors.forename: Andrew Q
authors.initials: AQ
authors.lastname: Tran
authors.forename: Jordan C
authors.initials: JC
authors.lastname: Wengrod
authors.forename: Owen N
authors.initials: ON
authors.lastname: Witte
authors.forename: Michael E
authors.initials: ME
authors.lastname: Phelps
authors.forename: Nagichettiar
authors.initials: N
authors.lastname: Satyamurthy
authors.forename: Johannes
authors.initials: J
authors.lastname: Czernin
authors.forename: Caius G
authors.initials: CG
authors.lastname: Radu
mesh_terms: D000227:Adenine Nucleotides; D000818:Animals; D001087:Arabinonucleosides; D001667:Binding, Competitive; D001711:Biotransformation; D002460:Cell Line; D002851:Chromatography, High Pressure Liquid; D000077866:Clofarabine; D003842:Deoxycytidine Kinase / Q000378:metabolism*; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D008232:Lymphoproliferative Disorders / Q000000981:diagnostic imaging; D051379:Mice; D010766:Phosphorylation; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals / Q000138:chemical synthesis / Q000493:pharmacokinetics; D011994:Recombinant Proteins; D013379:Substrate Specificity; D014055:Tomography, Emission-Computed; D051598:Whole Body Imaging
chemical_list: D000227:Adenine Nucleotides; D001087:Arabinonucleosides; D019275:Radiopharmaceuticals; D011994:Recombinant Proteins; D000077866:Clofarabine; D007770:L-Lactate Dehydrogenase; D003842:Deoxycytidine Kinase